Vimarsana
Biggest News Aggregation in the World

Investigational Testing Authorization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Investigational Testing Authorization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Investigational Testing Authorization Today - Breaking & Trending Today

Varian Users Achieve Key Milestones in Adoption of HyperSight Imaging Solution - Vimarsana News

Varian Users Achieve Key Milestones in Adoption of HyperSight Imaging Solution

The company celebrates key milestones as its users continue to adopt the new HyperSight imaging solution on the Ethos and Halcyon radiotherapy systems

Varian Users Achieve Key Milestones in Adoption of HyperSight Imaging Solution - Vimarsana News

Varian Users Achieve Key Milestones in Adoption of HyperSight Imaging Solution

/PRNewswire/ -- Varian, a Siemens Healthineers company, today shared two key milestones as its users continue to adopt the new HyperSight™ imaging solution on...

MedMira, Inc.: Update on MedMira's Reveal TP Clinical Trials in Canada - Vimarsana News

MedMira, Inc.: Update on MedMira's Reveal TP Clinical Trials in Canada

HALIFAX, NS / ACCESSWIRE / March 14, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP (Syphilis) antibody test.

Alpha Tau Announces Multiple Corporate Updates Ahead of - Vimarsana News

Alpha Tau Announces Multiple Corporate Updates Ahead of

- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes...

MedMira Provides a Pre-Annual General Meeting Update - Vimarsana News

MedMira Provides a Pre-Annual General Meeting Update

HALIFAX, Nova Scotia, Feb. 04, 2022 -- Today, MedMira Inc. provides a pre-Annual General Meeting update on its regulatory and product development progress. This includes its COVID-19 and its... | February 4, 2022